10 Best Small-Cap Biotech Stocks to Buy According to Analysts

6. Structure Therapeutics Inc. (NASDAQ:GPCR)

Number of Hedge Fund Holders: 44

Upside Potential: 105.73%

With significant upside potential, Structure Therapeutics Inc. (NASDAQ:GPCR) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts.

On November 10, 2025, BMO Capital reiterated its “Outperform” rating on Structure Therapeutics Inc. (NASDAQ:GPCR), setting a $100 price target. The firm cited upcoming ACCESS I and II Phase 2b obesity trial readouts, believing they could bolster the company’s competitive position in the weight-loss drug market. The investment firm highlighted easing expectations following Eli Lilly’s recent data, which makes Structure’s results a crucial benchmark.

Meanwhile, Structure Therapeutics Inc. (NASDAQ:GPCR) reported its Q3 2025 results on November 6. The quarter saw the company reaffirm that its ongoing obesity studies remain on track for year-end. In the quarter, the company also noted progress on its oral amylin receptor agonist programs. However, research costs came out high, reaching $59 million, which the company expects to remain elevated due to upcoming trial spending. The net loss widened to $65.7 million, compared to $34 million in Q3 2024.

Structure Therapeutics Inc. (NASDAQ:GPCR) ended the quarter with a strong cash position of $799 million, which will support the company’s continued development and planned study initiations through 2026.

Structure Therapeutics Inc. (NASDAQ:GPCR), a biopharmaceutical company, develops oral small-molecule treatments for metabolic diseases.